Serving as a field-based extension of Medical Affairs, the Medical Science Liaison (MSL) will represent the Company and their investigational, drug currently being evaluated for the treatment of adolescent and adult patients with Attention-Deficit/Hyperactivity Disorder (ADHD), as well as additional pipeline products as appropriate.
The MSL will build long-term peer to peer relationships with thought leaders, payers and other stakeholders within the healthcare community to deliver robust clinical conversations, providing and delivering presentations and testimonies, building customer relationships, and leading strategic discussions as it relates to key clinical issues/concepts, and health economic and outcomes research data on Company products. The MSL is responsible for engaging, cultivating and maintaining collaborative relationships with influential members of the medical community by engaging with a variety of different healthcare professionals across the spectrum of the healthcare system including physicians, nurses, pharmacists, and physician assistants in the clinic/practice/institution setting, and with medical and pharmacy directors, formulary committees, case managers, Medicaid decision-makers, and others in the managed care setting. Through these interactions, the MSL will assess changes to and emerging pressures on practice environments and understand local, regional, and national initiatives relevant to Company business. These scientific exchanges will support and/or expand current therapeutic concepts, as well as ensure the safe and effective utilization of Company product(s).
Clinical and Hospital/Institution setting